Tesa/IPA Protocol (Tesa-IPA)
Tesamorelin + Ipamorelin GH Secretagogue Blend
Community Research
Join others researching Tesa/IPA Protocol — share findings, ask questions, and learn from real experiences
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.
Molecular Data
Tesamorelin (GHRH analog) + Ipamorelin (GHRP) Complex or non-standard sequence format
Research Indications
Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
Enhanced GH promotes protein synthesis and lean tissue preservation.
GH secretagogues often improve deep sleep quality.
Enhanced GH supports tissue repair and recovery from exercise.
Restoring more youthful GH levels may provide anti-aging benefits.
Tesamorelin has shown improvements in lipid parameters in studies.
Increased GH leads to increased IGF-1 production.
Dosing Protocols
Subcutaneous injection, typically administered before bed or in the morning on an empty stomach. Evening dosing may enhance natural nighttime GH pulse. Avoid eating 2-3 hours before and 30-60 minutes after injection for optimal results.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol (5/5 blend) | 200-400mcg total | Once daily (evening) | SubQ |
| Enhanced protocol (10/3 blend) | 300-500mcg total | Once daily (evening) | SubQ |
| Twice daily (advanced) | 200-300mcg per dose | Morning and evening | SubQ |
Reconstitution Instructions
- Tesa/IPA vial (5/5mg or 10/3mg)
- Bacteriostatic water (2-3mL)
- Insulin syringes
- Alcohol prep pads
- 1 Clean vial top with alcohol pad
- 2 Add 2mL bacteriostatic water for convenient dosing
- 3 Gently swirl - do not shake
- 4 Solution should appear clear
- 5 Label with date and concentration
- 6 Store refrigerated immediately
- 7 Use within 4-6 weeks
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Injection site reactions (redness, itching)
- Water retention (usually transient)
- Tingling or numbness in extremities
- Joint stiffness
- Increased hunger (Ipamorelin effect)
Stop Signs - Discontinue if:
- Severe injection site reactions
- Significant swelling or edema
- Signs of glucose dysregulation
- Severe joint pain
- Allergic reactions
Contraindications
- Active malignancy (GH may promote tumor growth)
- Diabetic retinopathy
- Pregnancy or breastfeeding
- Pituitary disorders
- Hypersensitivity to components
Quality Checklist
Good Signs
- Third-party testing confirming both components
- Certificate of Analysis with ratios verified
- Reputable research supplier
- Proper cold chain shipping
Warning Signs
- Tesamorelin is FDA-approved as Egrifta - research blends are not
- Ipamorelin remains investigational
Bad Signs
- No Certificate of Analysis
- Cannot verify Tesamorelin:Ipamorelin ratio
- Discolored or particulate solution
References
- Metabolic effects of a growth hormone-releasing factor in patients with HIVFalutz J, Allas S, Blot K, et al.New England Journal of Medicine (2007)
Landmark RCT in 412 HIV patients: tesamorelin 2 mg daily for 26 weeks reduced visceral fat by 10.9% vs 0.6% placebo, improved lipid profiles with no change in subcutaneous fat.
- Ipamorelin, the first selective growth hormone secretagogueRaun K, Hansen BS, Johansen NL, et al.European Journal of Endocrinology (1998)
Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.
- GHRH + GHRP SynergyEndocrine Reviews
Combining GHRH and GHRP pathways produces synergistic GH release greater than either agent alone, driven by independent receptor mechanisms on pituitary somatotrophs.
- No Published Studies on Tesa/IPA CombinationN/A (2024)
No clinical trials have evaluated the specific tesamorelin + ipamorelin blend; synergy is inferred from GHRH/GHRP pharmacology and individual component data.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.